Compare SITE & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SITE | PTCT |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.5B |
| IPO Year | 2015 | 2006 |
| Metric | SITE | PTCT |
|---|---|---|
| Price | $129.78 | $67.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $154.38 | $80.94 |
| AVG Volume (30 Days) | 516.8K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.35 | ★ 264.48 |
| EPS | 3.37 | ★ 7.78 |
| Revenue | ★ $4,704,800,000.00 | $264,734,000.00 |
| Revenue This Year | $6.68 | N/A |
| Revenue Next Year | $4.28 | $21.65 |
| P/E Ratio | $38.51 | ★ $8.64 |
| Revenue Growth | 3.62 | ★ 36.19 |
| 52 Week Low | $101.25 | $35.95 |
| 52 Week High | $168.56 | $87.50 |
| Indicator | SITE | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 47.74 |
| Support Level | $123.78 | $61.43 |
| Resistance Level | $135.92 | $69.29 |
| Average True Range (ATR) | 3.80 | 2.58 |
| MACD | -1.00 | 0.44 |
| Stochastic Oscillator | 15.84 | 60.76 |
SiteOne Landscape Supply Inc is a supplier of tools and equipment. The company serves various businesses which include wholesale irrigation, outdoor lighting, nursery, landscape supplies, grass seeds, and fertilizers, turf protection products, turf care equipment, and golf course accessories for green industry professionals mainly in the United States and Canada. Its product portfolio includes irrigation supplies, fertilizer and herbicides, landscape accessories, nursery goods, natural stones and blocks, outdoor lighting and ice melt products and other products.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.